GameSquare Announces Pricing of Underwritten Public Offering to Launch Ethereum Treasury Strategy
Initial investment fuels GameSquare's strategic alliance with Ryan Zurrer and Dialectic to deploy an Ethereum-native yield strategy
GameSquare Holdings, Inc. (NASDAQ:GAME), ("GameSquare", or the "Company"), a next-generation media, entertainment, and technology company, today announced the pricing of its previously announced underwritten public offering for the sale of 8,421,054 shares of common stock (or common stock equivalents) at a price of $0.95 per share for expected aggregate gross proceeds of approximately $8.0 million before deducting underwriting discounts and commissions and offering expenses. The Company intends to use the majority of the proceeds to accelerate the launch of its newly formed Ethereum ("ETH") based treasury strategy, supported by a strategic alliance with Dialectic, a global leader in crypto-native capital management.
"Today's announcement reflects the confidence of a proven group of high-quality investors and leaders in decentralized finance," said Justin Kenna, CEO of GameSquare. "We've partnered with one of the world's top crypto investment firms to generate real, on-chain yield while deepening our expertise in decentralized finance, pursuing new revenue streams, and strengthening our balance sheet."
"This new treasury management strategy enhances our financial flexibility and allows us to support a defined capital allocation plan that is focused on pursuing additional ETH asset purchases, funding potential share repurchases, and reinvesting in our growth initiatives," added Kenna.
GameSquare's ETH-focused yield generation strategy is built on top of Dialectic's proprietary platform Medici, which applies machine learning models, automated optimization, and multi-layered risk controls to generate best-in-class risk-adjusted returns. Targeted yields of 8-14% significantly exceed the current ETH staking benchmarks of 3-4%.
Dialectic's program includes multi-layered risk management protocols that are widely recognized as the best risk-adjusted yields in DeFi. GameSquare's new Ethereum-focused treasury vehicle may also incorporate additional yield-generating strategies across the Ethereum ecosystem, potentially utilizing assets such as stablecoins and non-fungible tokens to diversify and amplify returns.
GameSquare's Board has approved an ETH allocation of up to $100 million, based on staged investments over time, while keeping adequate working capital for the operating business.
"Our crypto strategy reinforces our existing foundation in gaming, technology, and media, and is aligned with the broader trend of institutional adoption of digital assets," Kenna continued. "Our strategic partnership with leaders in the crypto space including Ryan Zurrer of Dialectic and Rhydon Lee of Goff Capital is just getting started and I am excited to update investors on the quick progress we are making."
Lucid Capital Markets is acting as the sole book-running manager for the offering.
In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 1,263,157 shares of its common stock (or common stock equivalents) at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about July 9, 2025, subject to customary closing conditions.
The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission ("SEC") on March 4, 2025, and declared effective by the SEC on June 4, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at www.sec.gov. A final prospectus supplement will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.
About GameSquare Holdings, Inc.
GameSquare 's (NASDAQ: GAME) mission is to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Their next-generation media, entertainment, and technology capabilities drive compelling outcomes for creators and maximize the brand partners' return on investment. Through a purpose-built platform, they provide award-winning marketing and creative services, offer leading data and analytics solutions, and amplify awareness through FaZe Clan Esports, one of the most prominent and influential gaming organizations in the world. With one of the largest gaming media networks in North America, as verified by Comscore, GameSquare is reshaping the landscape of digital media and immersive entertainment.
To learn more, users can visit www.gamesquare.com.
Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company's future performance, revenue, growth and profitability; and the Company's ability to execute on its current and future business plans. These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company's ability to grow its business and being able to execute on its business plans, the success of Company's vendors and partners in their provision of services to the Company, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company's ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company's portfolio across entertainment and media platforms, dependence on the Company's key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company's most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Corporate Contact
Lou Schwartz, President
Phone: (216) 464-6400
Investor Relations
Andrew Berger
Phone: (216) 464-6400
Email: ir@gamesquare.com
Media Relations
Chelsey Northern / The Untold
Phone: (254) 855-4028
Contact
President
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
38 minutes ago
- Business Insider
Mobileye sees Q2 revenue $502M-$506M, consensus $466.4M
In a regulatory filing, the company has commented on Recent Developments impacting its operations stating: 'Events in Israel: On June 13, 2025, Israel launched a preemptive attack on Iran, to which Iran responded with ballistic missile and drone attacks. On June 23, 2025, Israel and Iran agreed to a ceasefire, although there is no assurance that the ceasefire will continue. How long and how severe the current conflict may become is unknown at this time, and any continued clash among Israel and Iran or other countries or militant groups in the region may escalate in the future into a greater regional conflict. The Company expects that the current conflict as well as the security escalation in Israel will not have a material impact on its business results in the short term. The Company has a business continuity plan in place to address a range of scenarios, including potential escalations, which it believes has proven effective over the past 18 months. However, since these are events beyond the Company's control, their continuation or cessation may affect the Company's expectations. The Company continues to monitor political and military developments closely and examine the consequences for its operations and assets. Agreement with TSMC (TSM): The Company has a long-standing relationship with STMicroelectronics to manufacture its EyeQ products. As part of an effort to establish redundancy and better control of its supply chain, the Company has sought additional qualified suppliers, and it has recently entered into an agreement with TSMC under which it will manufacture components of the Company's imaging radar and some of its future generations of its EyeQ product, and potentially other future products.'
Yahoo
an hour ago
- Yahoo
Could Apple Soon Lose Its Top Position in Warren Buffett's Portfolio?
Apple has been one of Warren Buffett's largest holdings for years, but the distance between second spot has been shrinking. Buffett has been unloading Apple stock and it has also been falling in value. 10 stocks we like better than Apple › Warren Buffett has famously referred to iPhone maker Apple (NASDAQ: AAPL) as "probably the best business I know in the world." It's long been one of Buffett's favorite stocks, and it has been a staple in the Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) portfolio for years. But while it still remains the top holding in the portfolio, it may not stay in that position for much longer. Here's why that could happen and what it might mean for investors. It wasn't all that long ago when Apple was easily the largest holding in Berkshire's portfolio, and it wasn't even close. As of the end of 2023, Apple accounted for half of the entire portfolio and was worth more than $174 billion. The next-largest holding was Bank of America, which accounted for just 10% of the portfolio and was worth a little less than $35 billion at the time. The idea of Apple falling in the second spot just didn't look like a conceivable scenario. However, with Buffett selling Apple stock since then and shares of the tech giant also falling, that has resulted in a much different makeup of Berkshire's portfolio today. Berkshire's position in Apple has been trimmed by two-thirds and was worth nearly $67 billion as of the end of March. While that was still good enough for the top spot and represented 26% of all holdings, the second spot, which belonged to American Express, accounted for 16% of the portfolio and was worth nearly $41 billion. Today, the gap is even thinner, with Apple's share of the Berkshire portfolio coming in at just under 22% versus nearly 17% for American Express. Apple has been a beloved Buffett stock for years, but amid fears of a rising capital gains tax rate, the billionaire investor has been drastically reducing his company's position in the tech giant. Even if Buffett doesn't sell any more Apple shares, the stock's falling valuation could lead to it falling to the second-largest holding in the fund in the near future. Shares of Apple are down 6% over the past 12 months, while American Express has risen by more than 37% over that stretch (returns as of July 7). Investors have been bearish on Apple over the slow rollout of artificial intelligence (AI) features for its latest iPhone. Without a drastic change and a way to convince investors that it's still a good growth stock and the business isn't falling behind its rivals, this downward trend may continue. In the longer term, I could see Apple even leaving the Berkshire portfolio permanently. Buffett is stepping down as CEO this year, at which point Greg Abel will take over. Under new leadership, there could be greater changes ahead, including potentially exiting the company's position in Apple and opting for stocks that may be better positioned for growth in AI. While that's not a guarantee, it may be a plausible scenario, especially if Apple struggles to show that it can keep up with its key competitors. Whether Apple is or isn't in Berkshire's portfolio shouldn't dictate whether you buy the stock or not. It may impact the stock in the short term as Buffett fans may follow suit and sell shares of Apple as well. Ultimately, however, whether you buy the stock or not should depend on your long-term investing strategy. If you're willing to be patient and invest in a blue chip stock that has phenomenal financials, including annual free cash flow of around $100 billion, then this can be a good investment to put into your portfolio today. While it may be a volatile road ahead for Apple, with a strong ecosystem of products and ample resources at its disposal, I'm confident the company can be a big player in AI and turn things around -- it's just a matter of how long it may take for that to happen. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $695,481!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $969,935!* Now, it's worth noting Stock Advisor's total average return is 1,053% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Bank of America is an advertising partner of Motley Fool Money. American Express is an advertising partner of Motley Fool Money. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Bank of America, and Berkshire Hathaway. The Motley Fool has a disclosure policy. Could Apple Soon Lose Its Top Position in Warren Buffett's Portfolio? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions. Cogent intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib as well as for working capital and general corporate purposes. J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering. The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission (SEC) on February 10, 2023 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering were filed with the SEC on July 8, 2025. A final prospectus supplement and the accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained at the SEC's website at or by request to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@ and postsalemanualrequests@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors, a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the completion of the public offering and the use of proceeds therefrom, are forward-looking statements. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to our capital position and the sufficiency of our capital to fund our operations in future periods; our use of the net proceeds of the underwritten public offering; risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the underwritten public offering; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in our filings with the SEC, including our Registration Statement on Form S-3ASR, which was filed with the SEC on February 10, 2023 and automatically became effective upon filing, as may be amended from time to time, together with the accompanying base prospectus contained therein and the documents incorporated by reference therein, including our most recent Annual Report on Form 10-K, our Quarterly Report on Form 10-Q and our subsequent periodic reports filed with the SEC, and the preliminary prospectus supplement related to this offering. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Contact: Christi WaarichSenior Director, Investor
